They have plenty of cash to get where they need to. If they go it alone, guess what...they will get a partner for ex-US for starters.
Worth more, so voted thumbs down... your question is a double negative...may be confusing on the vote. That said, in a BO you have to give the acquirer some reason to buy it so they can make a profit taking on risk and commercialization, etc.
You could have just required health insurers to take folks with preexisting conditions versus turning the whole industry upside down to government run. Kinda like this, one Company Jack's up the price of one drug, now they want price controls. Tha system would have solved it by insurers taking the drug off approved covered drugs, or a better drug would come along.
Ugh???? They aren't doing another secondary for a couple of years. They may not need one at all, if partner or BO. How clueless are you.
Listening to the CEO, I think the data must be looking good. Not sure if it's all in.CEMP's Soli potential is huge., I still have hope for TTPH, in the gram negative space.
Non-Inferiority gets approval. CEMP is dirt cheap either with non-superiority or with Superiority. What's the problem...there isn't one. Just keep adding at these ridiculous prices.
A true no brainer.After all the data, if good, (COPD, IV,and Gono), EU partner, NDA submission, I am looking at the $75-$100 area. Then BO.$125-$150. After COPD Sept, $50-$60 if good.
When was the 10th patient enrolled? Also if you see the centers accelerating enrollment after a period of time...I look to that as the physicians seeing positive results.
Heading to PHIII not PHII. Back test what? More like no one wants to be in the market right now. That could change. China fears not all that relevant to healthcare sector. Getting to be almost laughable.